MoonLake outlines more data in psoriatic arthritis as it preps for pivotal trials: #AAD24
10 Mar 2024
Phase 2Clinical ResultPhase 3
MoonLake Immunotherapeutics on Sunday touted updated data from a Phase II psoriatic arthritis trial thatwas met with skepticism last year, and has now outlined its Phase III path forward.
After 24 weeks, 61% of patients taking the 60 mg dose of sonelokimab saw at least a 50% reduction in swollen and tender joints, while 58% taking the 120 mg dose responded to that level. Those figures fell in range of analyst expectations, with TD Cowen’s Phil Nadeau estimating about a 60% response rate on this measure.
Preview
Source: EndPoints
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
SIGN UP
LOG IN
BECOME A PREMIUM SUBSCRIBER
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-Drugs
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.